BGLAF (BioGaia AB) Tariff Resilience Score: 6/10 (As of Jun. 28, 2026)


BGLAF BioGaia AB BGLAF
100 GF Score
Price $12.20
GF Value $13.05
! 5 Warning Signs
View Full Analysis

What is BioGaia AB Tariff Resilience Score?

BioGaia AB BGLAF 100 Tariff Resilience Score is 6 as of Jun. 28, 2026. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.05. The stock has 5 warning signs investors should review. Among 1,028 Drug Manufacturers companies, BioGaia AB ranks better than 91.15% on this metric.

BioGaia AB has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

BioGaia AB has BioGaia AB, a Swedish company, exports globally, facing moderate tariff exposure. It has diversified markets and some pricing power, but tariffs can impact competitiveness in key regions.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes BioGaia AB might have Average Resilient.

BioGaia AB  (OTCPK:BGLAF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

BioGaia AB Tariff Resilience Score Related Terms

BGLAF vs ZTS: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioGaia AB Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where BioGaia AB's Tariff Resilience Score falls into.


BGLAF
100GF Score
BioGaia AB BGLAF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
BioGaia AB (BGLAF) has a Tariff Resilience Score of 6 as of Jun. 28, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, BioGaia AB ranks #91 out of 1028 companies in the Drug Manufacturers industry, placing it in the top 8.9%.
Is BioGaia AB's Tariff Resilience Score too high?
BioGaia AB's current Tariff Resilience Score is 6. Based on the distribution chart, BioGaia AB ranks #91 out of 1028 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Tariff Resilience Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #91 out of 1028 companies for Tariff Resilience Score. This places BioGaia AB in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. BioGaia AB's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
BioGaia AB (BGLAF) has a current Tariff Resilience Score of 6. The stock's GF Value™ is $13.05, compared to a current price of $12.20 — trading 6.5% below its estimated fair value. The current Tariff Resilience Score is 6. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Tariff Resilience Score is 6 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioGaia AB (BGLAF) Overvalued in 2026?

Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued. The current stock price of $12.20 is trading 6.5% below its estimated GF Value™ of $13.05.

Key valuation signals for BGLAF:

  • Tariff Resilience Score: 6
  • GF Value™: $13.05 vs. price of $12.20 (6.5% below fair value)
  • GF Score™: 100/100 with 5 warning signs

No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioGaia AB Business Description

Address Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score

Get the complete analysis for BGLAF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.20
Price
$13.05
GF Value